FDA Approved: ADALIMUMAB — Supplemental Application (Sandoz Inc)

View source ↗

Summary

FDA approval of a supplemental application for the adalimumab biosimilar ADALIMUMAB-ADAZ from Sandoz Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis
• Crohn Disease
• Hidradenitis Suppurativa
• Juvenile Idiopathic Arthritis
• Plaque Psoriasis
• Psoriatic Arthritis
• Rheumatoid Arthritis
• Ulcerative Colitis

Drugs mentioned

• ADALIMUMAB-ADAZ (adalimumab)

Snippet

SUPPL AP for ADALIMUMAB (ADALIMUMAB-ADAZ)